Market Place
Sourcing Support
Vifor`s Tavneos (avacopan) Receives Approval in Europe
19 Jul 2023 //
EMA
Tavneos included in updated EULAR recommendations for the management of AAV
27 Mar 2023 //
PR NEWSWIRE
Vifor Pharma`s Tavneos (Avacopan) Approved In Europe
13 Feb 2023 //
EMA
Vifor`s Tavneos (Avacopan) Receives Approval in the Europe
25 Nov 2022 //
EMA
ChemoCentryx Announces TAVNEOS Presentations at Upcoming Medical Conferences
24 Aug 2022 //
GLOBENEWSWIRE
Tavneos recommended by England’s NICE for the treatment of AAV (GPA/MPA)
17 Aug 2022 //
BUSINESSWIRE
ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS
11 May 2022 //
GLOBENEWSWIRE
ChemoCentryx Announces EU Approval of TAVNEOS in ANCA-Associated Vasculitis
19 Jan 2022 //
GLOBENEWSWIRE
Vifor Fresenius` Tavneos (avacopan) Receives Approval in Europe
11 Jan 2022 //
EMA
Abstracts at Annual Meetings of ACN, ACR Highlight Potential Value of TAVNEOS
04 Nov 2021 //
GLOBENEWSWIRE
Coverage restrictions apply to recently-approved ANCA vasculitis drug
26 Oct 2021 //
CLINICALTRIALSARENA
PANTHERx® Rare Pharmacy Selected by ChemoCentryx to Distribute TAVNEOS™
14 Oct 2021 //
PRNEWSWIRE
Amber Specialty Pharmacy Selected by ChemoCentryx to Dispense TAVNEOS™
13 Oct 2021 //
BUSINESSWIRE
Amber Specialty Selected by ChemoCentryx to Dispense TAVNEOS
13 Oct 2021 //
BUSINESSWIRE
VFMCRP announces approval for TAVNEOS for ANCA-associated vasculitis in Japan
27 Sep 2021 //
BUSINESSWIRE
ChemoCentryx Announces Filing of Amendment to NDA Submission
06 Jul 2021 //
GLOBENEWSWIRE
ChemoCentryx Announces Abstract on Avacopan in ANCA-Associated Vasculitis
08 Jun 2021 //
GLOBENEWSWIRE
Submission of New Drug Application for Avacopan (CCX168)
01 Mar 2021 //
KISSEI
VFMCRP & ChemoCentryx announce EMA has accepted to review
02 Nov 2020 //
BUSINESSWIRE
ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan
09 Jul 2020 //
PRESS RELEASE
ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated
03 Jun 2020 //
GLOBENEWSWIRE
ChemoCentryx Drug Hits Co-Primary Endpoints in Phase III Vasculitis Trial
26 Nov 2019 //
BIO SPACE
ChemoCentryx pulls conditional approval filing to rejig regulatory plan
24 Jan 2019 //
FIERCE BIOTECH
Vynpenta (previously Avacopan): Withdrawal of the MA appln
02 Jan 2019 //
EMA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.